Humoral responses against mismatched donor HLA are routinely measured as serum HLA antibodies, which are mainly produced by bone marrow-residing plasma cells. Individuals with a history of alloimmunization but lacking serum antibodies may harbor circulating dormant memory B cells, which may rapidly become plasma cells on antigen reencounter. Currently available methods to detect HLA-specific memory B cells are scarce and insufficient in quantifying the complete donor-specific memory B cell response due to their dependence on synthetic HLA molecules. We present a highly sensitive and specific tool for quantifying donor-specific memory B cells in peripheral blood of individuals using cell lysates covering the complete HLA class I and class II repertoire of an individual. Using this enzyme-linked immunospot (ELISpot) assay, we found a median frequency of 31 HLA class I and 89 HLA class II-specific memory B cells per million IgG-producing cells directed at paternal HLA in peripheral blood samples from women (n = 22) with a history of pregnancy, using cell lysates from spouses. The donor-specific memory B cell ELISpot can be used in HLA diagnostic laboratories as a cross-match assay to quantify donor-specific memory B cells in patients with a history of sensitizing events.
Introduction
Preexistence or de novo development of donor-specific antibodies (DSAs) directed at mismatched donor HLA portends a major risk of adverse outcome for kidney, heart, lung, and, to some extent, liver transplantations (1) (2) (3) (4) . HLA antibodies may develop in an individual on exposure to allogeneic HLA via blood transfusions, pregnancies, or previous transplantations. B cells encountering allogeneic HLA molecules may differentiate into plasma cells producing HLA-specific antibodies as well as becoming circulating dormant memory B cells (5) . HLA antibodies produced by plasma cells can be detected directly in serum using complement-dependent cytotoxicity, ELISA, and bead-based assays. Although proven to be extremely informative, HLA antibody analyses in serum do not provide any information on the magnitude of the HLA-specific memory B cell pool (6) . Because HLA-specific memory B cells can rapidly differentiate into antibody-secreting cells on antigen rechallenge, there is a clinical need to detect these cells in transplant recipients. Therefore, several assays have been developed to quantify memory B cells directed to specific synthetic HLA molecules (7) (8) (9) (10) (11) (12) . Considering the enormous polymorphism of the HLA system, it is very unlikely to be able to cover the complete HLA repertoire of an individual, even if all combinations of synthetic HLA molecules are used. Consequently, we aimed to develop an assay in which donor HLA containing cell lysates is used as a detection matrix in enzyme-linked immunospot (ELISpot) assays. In this study, we present a donor-specific ELISpot assay capable of detecting and quantifying HLAspecific memory B cells using peripheral blood or spleen cell lysates in polyclonally activated peripheral blood samples of alloantigen immunized individuals.
Materials and Methods

Cells
Peripheral blood samples from healthy volunteers and spleen samples from deceased organ donors were obtained with informed consent under guidelines issued by the medical ethics committee of Leiden University (Leiden, the Netherlands). Mononuclear cells from peripheral blood or spleen were isolated by Ficoll-Hypaque density gradient centrifugation and kept frozen in liquid nitrogen until further use. A total of 27 peripheral blood samples from HLA-typed healthy women (n = 22) with a history of at least one pregnancy were collected and tested against immunizing HLA using donor-specific ELISpot assays. In addition, peripheral blood samples from 10 men without any history of immunizing events and serum HLA antibodies were assessed for the presence of HLA-specific memory B cells by donor-specific ELISpot assays.
Human B cell hybridomas producing HLA class I or class II-specific monoclonal antibodies were used for the development and optimization of the donor-specific ELISpot assays (13, 14) .
Lysate preparation
Lysates were prepared from either peripheral blood mononuclear cells (PBMCs) or spleen cells. Mononuclear cells from peripheral blood or spleen samples (1 9 10 6 cells per well in 24-well plates) were stimulated for 7 days with 2 lg/mL phytohemagglutinin (Remel, Dartford Kent, UK) and 60 IU/mL IL-2 (Proleukin; Novartis, Amsterdam, the Netherlands) in Iscove's modified Dulbecco's medium (IMDM; Gibco Invitrogen, Paisley, UK) containing 10% fetal bovine serum (FBS; Gibco Invitrogen) and 100 U/mL penicillin with 100 lg/mL streptomycin (Gibco Invitrogen). 
ELISpot assays
Total IgG ELISpot assays were performed, as described previously (17 
Statistical analysis
The Mann-Whitney U test was used for comparisons of the results between groups. The Tukey method was used to find the outlier values in HLA class I and class II-specific B cell frequencies in samples from nonimmunized men and to define the donor-specific ELISpot assay cutoff using the following formula: third quartile+(1.5 9 interquartile range). Statistical level of significance was defined as p < 0.05.
Results
Cell lysates can be used to detect HLA-specific antibody-producing cells Human B cell hybridomas producing monoclonal HLA antibodies were used to develop and optimize the donorspecific memory B cell ELISpot assays. We previously showed that synthetic HLA molecules could be used as detection agents to capture HLA antibody-producing cells with high sensitivity and specificity (10) . Using the same approach, we used cell lysates as detection matrix for quantification of HLA-specific B cell hybridomas. Initially, we tested whether each HLA specificity in single lysates was recognized by corresponding specificity of HLA antibody-producing hybridoma cells. To this end, we prepared several lysates positive for different HLA molecules. As shown in Figure 1 (A), an HLA class I PBMC lysate positive for HLA-A1, HLA-B7, and HLA-B13 was tested against three different hybridoma cells producing antibodies directed at HLA-A1, HLA-B7, or HLA-B13. All antibody-producing cells from each corresponding hybridoma were detected with high sensitivity using the same lysate, as evident by comparable numbers of spots between donor-specific and total IgG ELISpot assays ( Figure 1A ). Similar results were found when a class I lysate positive for HLA-A1, HLA-A2, HLA-B7, and HLA-B18 was prepared from spleen mononuclear cells and tested against hybridoma cells producing corresponding specificity of HLA antibodies, indicating the potential of using cell lysates covering multiple HLA specificities in quantifying HLA-specific B cells ( Figure 1B ).
To verify lysate stability with freezing and thawing, we analyzed spot numbers obtained in donor-specific ELISpot assays after freezing and thawing at several time points. As shown in Figure 2 (A), spot counts comparable to total IgG ELISpot assays were found by using a donor-specific ELISpot assay when a freshly made or 4-day frozen HLA-A1 + lysate was used to detect HLA-A1 antibody-producing cells. Similarly, HLA-A1-producing cells were still detected with high sensitivity when 2 or 3-year frozen class I lysates were used, as evident by comparable spot counts between donor-specific and total IgG ELISpot assays. Likewise, similar spot counts were obtained when short-term (1 day) or longer term (36 days) frozen class II lysates were used to detect HLA-DR11 antibody-producing hybridoma cells, suggesting that long-term storage did not affect HLA class I or class II stability in the lysates ( Figure 2B ).
Because the cell lysates contain various HLA antigens, we next questioned whether B cell hybridomas were detected with correct specificity in donor-specific ELISpot assays. To this aim, we prepared PBMC lysates from HLA-A1 + and HLA-A1 À individuals and tested these lysates against HLA-A1 antibody-producing hybridoma cells. Clear spot formation was found when an HLA-A1 + lysate was used, whereas no significant spot formation was observed with HLA-A1 À lysates. Likewise, when lysates positive for HLA-B13 or lacking HLA-B13 were used to quantify HLA-B13 antibody-producing cells, spot counts with HLA-B13 + lysates were comparable to total IgG spots while no spots were formed when HLA-B13 À lysates were used ( Figure 3A ). Similar results were found for HLA class II lysates prepared from PBMCs or spleen mononuclear cells to detect hybridoma cells (RTLK1E2) producing anti-HLA-DR3, -DR8, -DR11, -DR12, -DR13, and -DR14 ( Figure 3B ). Use of lysates containing HLA-DR11 and -DR15 or HLA-DR12 and -DR13 resulted in spot formation, whereas no spots were observed when HLA-DR7 and -DR9 or HLA-DR9 and -DR10-containing lysates were used, confirming that spots were detected with correct specificity in donor-specific ELISpot assays.
Paternal HLA-specific B cells can be detected in peripheral blood of women with a history of pregnancy Having shown that the donor-specific ELISpot allowed for quantification of HLA antibody-producing hybridoma cells, we aimed to determine whether HLA-specific memory B cells directed at paternal HLA could be detected in peripheral blood samples from women with history of pregnancy, using paternal (n = 14) or paternallike (n = 21) cell lysates sharing the immunizing HLA antigens with the spouses (Table S1 ). A total of 24 HLA class I and 27 HLA class II-specific assays were performed using donor or donor-like cell lysates with peripheral blood samples from parous women ( Table 1) .
As shown in Figure 4 , memory B cells could be visualized as single spots in donor-specific ELISpot assays when polyclonally activated PBMC samples from women with a history of pregnancy were tested against cell lysates containing paternal HLA class I or class II molecules. As expected, no significant spot formation was found against self HLA class I or class II molecules, confirming the specificity of the assay.
We found significantly higher HLA class I-specific memory B cells (median frequency 202, range 0-802) in women with serum HLA class I antibodies compared with those without serum HLA class I antibodies (median frequency 0, range: 0-8) and nonimmunized men (median 0, range 0-25; p < 0.0001) ( Figure 5A ). Similarly, HLA class II-specific memory B cell frequencies were significantly higher in the group of women with serum HLA class II antibodies (median frequency 137, range 0-1050) compared with women without serum antibodies (median frequency 1, range 0-19; p < 0.05) and nonimmunized men (median frequency 0, range 0-26; p < 0.0001) ( Figure 5B ). HLA-specific memory B cell frequencies did not differ between women without serum HLA antibodies and nonimmunized men (p-value not significant).
HLA ELISpot assay cutoff
To define a cutoff value for positive responses in donorspecific ELISpot assays, polyclonally activated PBMC samples from men without any history of sensitizing events were tested against cell lysates that were at least one-locus mismatched for HLA class I and/or class II. ELISpot assays were performed testing nine men against two different lysates and one man against four different lysates for class I and six men with three different lysates for class II. The median frequencies of HLA class I-specific (range 0-25) and class II-specific (range 0-26) B cells per million IgG + cells were found to be 0 in samples from nonimmunized men tested against non-self HLA-containing lysates. To establish a cutoff for positive responses in donor-specific ELISpot assays, we first defined the outlier values separately for HLA class I and II frequencies in nonimmunized men. Accordingly, we established HLA-specific B cell frequencies >6 (for class I) and >18 (for class II) per million IgG + cells as positive.
When we classified pregnancy-immunized women into two groups as women with and without serum HLA antibodies and applied the donor-specific ELISpot assay cutoff, we found that all except two (sample 148, HLA class I frequency 0; sample 203, HLA class II frequency 0) in the serum antibody-positive group had paternal HLAspecific memory B cell frequencies above the cutoff for both class I and class II ( A B sample (sample 201) in the HLA class II serum antibodypositive group was found to have no HLA-DR12-specific memory B cells when a lysate expressing HLA-DRB1*12/13 was used, despite lysates bearing other HLA specificities and serum antibodies giving positive reactions (Table S1 ). In the serum HLA antibody-negative group, all except two samples (sample 159, HLA class I frequency 8; sample 151/207.3, HLA class II frequency 19) had HLA-specific memory B cell frequencies below the donor-specific ELISpot assay cutoff.
Discussion
We present, for the first time, a highly specific and sensitive tool to screen for donor-specific memory B cells in peripheral blood up on polyclonal activation using PBMC or spleen cell lysates as the HLA targets, representing the complete HLA class I and class II repertoire of an individual. Using these cell lysates, antibody-producing cells in the peripheral blood directed specifically to the allogeneic HLA contained in the lysate can be quantified in an ELISpot format. Currently available methods to quantify HLA-specific memory B cells in peripheral blood of alloantigen-immunized individuals are scarce and rely on synthetic HLA molecules (7) (8) (9) (10) (11) (12) 18) . B cell detection by HLA tetramers using flow cytometry is a simple method to quantify the percentage of HLA-specific B cells; however, to ensure that these HLA tetramer-positive B cells have the capacity to produce HLA antibodies, further sorting and culturing steps are required (7, 8) . By combining the ability of polyclonally activated B cells to produce HLA antibodies in vitro with the potential of these antibodies to bind synthetic HLA molecules, HLAspecific ELISpot assays enable quantification of HLA-specific memory B cells (9, 10) . Although HLA-specific ELISpot assays allow for detection and quantification of both HLA class I and class II-specific memory B cells by utilization of monomeric HLA molecules, they are limited to certain HLA specificities that are commercially available, restricting the clinical applicability. Previously, Lynch et al used donor-derived fibroblasts as the HLA targets to show the presence of donor-specific memory B cells directed toward donor HLA class I using ELISpot (19) . Difficulties in obtaining the donor material and the long culture time of fibroblasts (30 days) limit the applicability of this assay in routine clinical monitoring. Furthermore, because fibroblasts express only HLA class I molecules, this assay cannot be used to quantify the full donor HLA-specific memory B cell population.
Unlike the latter technique, the current assay allows for the quantification of both donor HLA class I and class IIspecific memory B cells. It is vital that every HLA specificity expressed by the donor cells is represented in the lysate as a specific detection matrix to be able to detect the complete repertoire of donor-specific memory B cells. Availability of a wide variety of HLA-A, -B and -DR-specific antibody-producing hybridoma cells in our laboratory enabled us to show that the donor-specific ELISpot assay is highly specific and equally sensitive to the total IgG ELISpot assay. Although we have tested various HLA specificities using B cell hybridomas and peripheral blood of pregnancy-immunized women in the lysate-based ELISpot assay, further validation is warranted. Previous research on the use of donor cell lysates in ELISA format suggests that many, if not all, specificities can be detected in lysates (20) , and this is confirmed by our findings so far. Importantly, we excluded the possibility that complexes of HLA class I and class II molecules in the lysate preparations could lead to false-positive signals ( Figure S3 ).
Polyclonal activation of peripheral blood B cells leads to differentiation of B cells into antibody-producing cells and allows for the detection of memory B cells in vitro (21).
The assay we present includes a 6-day preculture period in which PBMC samples are activated with a polyclonal activation cocktail that consists of TLR7/TLR8 agonist (R848) in combination with IL-2 and results in the preferential activation of memory B cells (16, 22) . This activation protocol does not induce class switching from na€ ıve B cells, as evident by the lack of IgG spots from na€ ıve B cell fractions ( Figure S4 ). The presence of IgG spots exclusively in the memory B cell fraction ensured that HLA-specific B cell frequencies obtained by the current donor-specific ELISpot assays were accurate estimations of HLA-specific memory B cell pools in the peripheral blood.
Alloimmunization through pregnancy is known to induce alloantibodies in 30-50% of women against the mismatched paternal HLA expressed on fetal cells, and these HLA antibodies can be detected in serum for decades after delivery (23) (24) (25) (26) . Using the donor-specific ELISpot assay, we found that 50% of women with a history of at least one pregnancy harbored memory B cells directed to paternal HLA in their peripheral blood sampled at a median time of 14 years after the last delivery in addition to the presence of serum HLA antibodies, demonstrating the long-term persistence of HLA-specific memory B cells.
In the present study, using the donor-specific ELISpot assays, we found median frequencies of 31 and 89 HLA class I and class II-specific B cells per million IgGproducing cells, respectively, in women with a history of pregnancy, whereas the median frequency of HLA-specific memory B cells in men without any history of immunization was 0 for both class I and class II. Using the outlier cutoff calculated from HLA-specific B cell frequencies in peripheral blood of nonimmunized men, we found that two women (samples 159 and 151/207.3) with history of pregnancy had HLA-specific B cells in the absence of serum antibodies, suggesting that HLA-specific memory B cells may be present in the absence of serum antibodies. Interestingly, in two samples that were obtained at different time points from a single pregnancy-immunized woman after delivery (sample 201.1 and 201.2), we could not detect HLA-DR12-specific memory B cells when HLA-DR12-containing cell lysates were used, which might be due to peptide selectivity of the HLA antibody (27) or reactivity with denatured HLA class II molecules on the beads (28).
Although we could not formally test whether HLA-DQ antibody-producing cells were detected due to the lack of appropriate B cell hybridomas, we observed spot formation in samples from pregnancy-immunized women (samples 201.1, 201.2, and 202) when lysates containing self or antibody-negative HLA-DR were used, suggesting that these spots were due to sole HLA-DQ specificity (Figure S5A-C) . Furthermore, by ELISA, we could demonstrate that HLA-C is present in the lysate preparations and can be used to detect HLA-C-specific memory B cells in ELISpot format (Figure S5D-F ).
In the current study, we tested PBMC samples from women with a history of immunization for the presence of paternal HLA-specific B cells using paternal cell lysates from spouses. This can readily be translated to HLA diagnostic laboratories as a "memory B cell crossmatch assay" because it allows for donor-specific memory B cell detection in PBMC samples of patients using cell lysates prepared from candidate donors in the setting of solid organ transplantation, in particular, for patients with a history of sensitizing events. A particularly important group of transplant recipients for this assay are women receiving transplants from their spouses, in whom sensitization in the absence of circulating antibodies may occur. In addition, patients undergoing desensitization therapies for prospective solid organ transplantation need to be monitored closely for DSA development during therapy as well as in the posttransplantation period. Quantification of donor-specific memory B cells in addition to serum antibody detection in this group of high-risk patients may aid better risk stratification and provide a comprehensive picture of the entire donor-specific B cell response (29) . Furthermore, longitudinal monitoring of patients for the presence of donor-specific memory B cells may, as such, provide insight into the evolution of the humoral alloimmune response after organ transplantation.
In summary, here we demonstrate, for the first time, a method that allows for detecting and quantifying donorspecific memory B cells in peripheral blood of individuals with a history of alloimmunization. While the current assay can be used to quantify IgG isotype of DSA-producing cells, it can also be used to detect antibody-producing cells of IgM isotype or IgG subclasses (30) . This donor-specific memory B cell ELISpot assay can serve as a memory B cell crossmatch assay to estimate the frequency of donor HLA-specific memory B cells, which have the capacity to produce HLA antibodies in a transplant recipient.
Supporting Information
Additional Supporting Information may be found in the online version of this article. To test whether HLA class I in the lysate could be complexed to HLA class II or vice versa, (A) we incubated enzyme-linked immunospot (ELISpot) plates with HLA-A1 antibody-producing hybridoma cells (WIM8E5) and added an HLA-A1 and HLA-DR3-containing peripheral blood mononuclear cell lysate, followed by either HLA class I or class II-specific detection antibodies. (B) For the HLA-A1-specific hybridoma, we found significant spot formation when the detection antibody was HLA class I-specific, (C) whereas no spot formation was found when the HLA class IIspecific detection antibody was used. (D) In parallel, we incubated ELISpot plates with HLA-DR3 antibodyproducing hybridoma cells (RTLK1E2), followed by adding the same lysate and detection antibodies for either HLA class I and II. (E) Similarly, spot formation was observed when HLA-DR3 antibody-producing hybridoma cells (RTLK1E2) were detected using the same lysate with HLA class II-specific detection (F), whereas no spot formation was observed when HLA class I-specific detection was applied. Lysates containing different HLA-C antigens were coated onto ELISA plates by anti-b2 microglobulin coating antibody and then tested against a human monoclonal antibody (TRA2G9) recognizing HLA-C*01:02, -C*03:02, -C*03:03, -C*03:04, -C*04:01, and -C*14:01. Reactivity of the monoclonal antibody with corresponding HLA-C antigens in lysates 1, 2, and 3 could be detected using a goat anti-human IgM antibody. (E) HLA-C antibody-producing cells can be detected in ELISpot format. The HLA-Cw1-specific IgM-producing hybridoma VP6G3 was tested against lysates containing various HLA-C molecules (lysate A: C*01, C*07; lysate B: C*01:02, C*07:02, lysate C: C*03:04, C*04:01; lysate D: C*03:04, C*04:01; and lysate E: C*07:01, C*07:02). Only lysates containing HLA-C*01 gave rise to spot formation. (F) Quantification of HLA-C-specific ELISpot assay. OD, optic density. Table S1 : HLA typing and the serum HLA antibody mean fluorescence intensity values of the study population.
